Jerman Michael Allen 4

What Happened

• Jerman Michael Allen, a director of Alaunos Therapeutics, received an award/acquisition of 6,032 shares of common stock on 2026-04-29 at an acquisition price of $2.59 per share, for a total value of $15,623. The filing indicates these shares were issued in lieu of board fees (compensation), not an open-market purchase.

Key Details

• Transaction date: 2026-04-29
• Price per share: $2.59; total value: $15,623
• Transaction type/code: Award/Acquisition (A)
• Footnote: F1 — shares issued in lieu of board fees (director compensation)
• Filing date: 2026-05-01 (filed within the Form 4 two-business-day deadline; not late)
• Shares owned after transaction: not specified in the filing

Context

• This was a compensation issuance (shares paid instead of cash for board service). Such awards are routine for directors and do not necessarily reflect personal buying or selling intent. The size of this issuance (~$15.6K) is relatively small compared with typical insider purchases/sales.